Institut de cancérologie du Gard
- Address
- Rue du Professeur Henri Pujol, 30029 Nîmes, France
Institut de cancérologie du Gard
The Institut de cancérologie du Gard is a specialized cancer research center dedicated to advancing treatment strategies for hematologic malignancies and solid tumors. The institute participates in innovative Phase II and Phase III clinical trials designed to optimize therapeutic approaches and improve outcomes for cancer patients.
- Myeloproliferative neoplasms including JAK inhibitor-naïve myelofibrosis with novel targeted therapies
- Hormone receptor-positive, HER2-negative early breast cancer with treatment de-escalation strategies
- Adjuvant therapy optimization using CDK4/6 inhibitors in intermediate-risk breast cancer
The center's research portfolio emphasizes both precision oncology approaches for rare hematologic disorders and adjuvant treatment optimization in breast cancer. Their participation in non-inferiority trials reflects a commitment to identifying effective treatment regimens that may reduce chemotherapy burden while maintaining excellent disease control, particularly in patients with intermediate-risk early breast cancer and those with thrombocytopenia-associated myelofibrosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut de cancérologie du Gard
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Selinexor Monotherapy in JAK Inhibitor-Naïve Myelofibrosis Patients with Moderate Thrombocytopenia | Karyopharm Therapeutics Inc. | Phase II | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2025-12-18 | 2025-12-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.